BBNX - Beta Bionics, Inc.

Beta Bionics Investor Alert: Johnson Fistel Reviews Potential Claims for Shareholders

SAN DIEGO, July 1, 2026 /PRNewswire/ -- Johnson Fistel, PLLP is investigating potential securities law violations on behalf of investors of Beta Bionics, Inc. (NASDAQ: BBNX). The investigation concerns whether Beta Bionics or certain of its executive officers made false or misleading statements, or failed to disclose material information, concerning the Company's growth trends, new patient starts, business outlook, and related operating metrics.

Jul 01, 2026 07:28 AM • prnewswire.com (Hide legal announcements)

Beta Bionics to Announce Second Quarter 2026 Financial Results on July 29, 2026

IRVINE, Calif., July 01, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it plans to release its second quarter 2026 financial results after the financial markets close on Wednesday, July 29, 2026.

Jul 01, 2026 04:30 AM • globenewswire.com

Beta Bionics Investor Alert: Johnson Fistel Reviews Potential Claims for Shareholders

SAN DIEGO, June 29, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential securities law violations on behalf of investors of Beta Bionics, Inc. (NASDAQ: BBNX). The investigation concerns whether Beta Bionics or certain of its executive officers made false or misleading statements, or failed to disclose material information, concerning the Company's growth trends, new patient starts, business outlook, and related operating metrics.

Jun 29, 2026 06:31 AM • globenewswire.com (Hide legal announcements)

Beta Bionics Investor Alert: Johnson Fistel Reviews Potential Claims for Shareholders

SAN DIEGO, June 29, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential securities law violations on behalf of investors of Beta Bionics, Inc. (NASDAQ: BBNX). The investigation concerns whether Beta Bionics or certain of its executive officers made false or misleading statements, or failed to disclose material information, concerning the Company's growth trends, new patient starts, business outlook, and related operating metrics.

Jun 29, 2026 06:31 AM • globenewswire.com (Hide legal announcements)

Beta Bionics Investor Alert: Johnson Fistel Reviews Potential Claims for Shareholders

SAN DIEGO, June 22, 2026 /PRNewswire/ -- Johnson Fistel, PLLP is investigating potential securities law violations on behalf of investors of Beta Bionics, Inc. (NASDAQ: BBNX). The investigation concerns whether Beta Bionics or certain of its executive officers made false or misleading statements, or failed to disclose material information, concerning the Company's growth trends, new patient starts, business outlook, and related operating metrics.

Jun 22, 2026 08:15 AM • prnewswire.com (Hide legal announcements)

Beta Bionics Investor Alert: Johnson Fistel Reviews Potential Claims for Shareholders

SAN DIEGO, June 17, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential securities law violations on behalf of investors of Beta Bionics, Inc. (NASDAQ: BBNX). The investigation concerns whether Beta Bionics or certain of its executive officers made false or misleading statements, or failed to disclose material information, concerning the Company's growth trends, new patient starts, business outlook, and related operating metrics.

Jun 17, 2026 08:06 AM • globenewswire.com (Hide legal announcements)

Beta Bionics Investor Alert: Johnson Fistel Reviews Potential Claims for Shareholders

SAN DIEGO, June 17, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential securities law violations on behalf of investors of Beta Bionics, Inc. (NASDAQ: BBNX). The investigation concerns whether Beta Bionics or certain of its executive officers made false or misleading statements, or failed to disclose material information, concerning the Company's growth trends, new patient starts, business outlook, and related operating metrics.

Jun 17, 2026 08:06 AM • globenewswire.com (Hide legal announcements)

Johnson Fistel Continues Investigation of Beta Bionics, Inc. (BBNX)

Johnson Fistel, PLLP is investigating potential securities law violations on behalf of investors of Beta Bionics, Inc. (NASDAQ: BBNX). The investigation concer

Jun 15, 2026 07:00 AM • gurufocus.com (Hide legal announcements)

Johnson Fistel Continues Investigation of Beta Bionics, Inc. (BBNX)

SAN DIEGO--(BUSINESS WIRE)---- $BBNX #BBNX--Johnson Fistel, PLLP is investigating potential securities law violations on behalf of investors of Beta Bionics, Inc. (NASDAQ: BBNX). The investigation concerns whether Beta Bionics or certain of its executive officers made false or misleading statements, or failed to disclose material information, concerning the Company's growth trends, new patient starts, business outlook, and related operating metrics. Beta Bionics Investors: Suffered Losses? Contact Johnson Fist.

Jun 15, 2026 06:25 AM • businesswire.com (Hide legal announcements)

Beta Bionics (BBNX) Securities Investigation: Johnson Fistel Reviews Investor Losses Following Slower New Patient Start Growth

Beta Bionics (BBNX) Securities Investigation: Johnson Fistel Reviews Investor Losses Following Slower New Patient Start Growth

Jun 12, 2026 09:00 AM • gurufocus.com (Hide legal announcements)

Beta Bionics (BBNX) Securities Investigation: Johnson Fistel Reviews Investor Losses Following Slower New Patient Start Growth

SAN DIEGO, June 12, 2026 /PRNewswire/ -- Johnson Fistel, PLLP is investigating potential securities law violations on behalf of investors of Beta Bionics, Inc. (NASDAQ: BBNX). The investigation concerns whether Beta Bionics or certain of its executive officers made false or misleading statements, or failed to disclose material information, concerning the Company's growth trends, new patient starts, business outlook, and related operating metrics.

Jun 12, 2026 08:50 AM • prnewswire.com (Hide legal announcements)

Beta Bionics (BBNX) Securities Investigation: Johnson Fistel Reviews Investor Losses Following Slower New Patient Start Growth

SAN DIEGO, June 11, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential securities law violations on behalf of investors of Beta Bionics, Inc. (NASDAQ: BBNX). The investigation concerns whether Beta Bionics or certain of its executive officers made false or misleading statements, or failed to disclose material information, concerning the Company's growth trends, new patient starts, business outlook, and related operating metrics.

Jun 11, 2026 08:34 AM • globenewswire.com (Hide legal announcements)

Beta Bionics (BBNX) Securities Investigation: Johnson Fistel Reviews Investor Losses Following Slower New Patient Start Growth

San Diego, California--(Newsfile Corp. - June 9, 2026) - Johnson Fistel, PLLP is investigating potential securities law violations on behalf of investors of Beta Bionics, Inc. (NASDAQ: BBNX). The investigation concerns whether Beta Bionics or certain of its executive officers made false or misleading statements, or failed to disclose material information, concerning the Company's growth trends, new patient starts, business outlook, and related operating metrics.

Jun 09, 2026 09:25 AM • newsfilecorp.com (Hide legal announcements)

Beta Bionics (BBNX) Securities Investigation: Johnson Fistel Reviews Investor Losses Following Slower New Patient Start Growth

SAN DIEGO, June 5, 2026 /PRNewswire/ -- Johnson Fistel, PLLP is investigating potential securities law violations on behalf of investors of Beta Bionics, Inc. (NASDAQ: BBNX). The investigation concerns whether Beta Bionics or certain of its executive officers made false or misleading statements, or failed to disclose material information, concerning the Company's growth trends, new patient starts, business outlook, and related operating metrics.

Jun 08, 2026 04:16 AM • prnewswire.com (Hide legal announcements)

Robbins LLP Reminds BBNX Stockholders of its Investigation into Beta Bionics, Inc.; Contact the Firm for Information

SAN DIEGO, June 05, 2026 (GLOBE NEWSWIRE) -- Shareholder rights law firm Robbins LLP is investigating Beta Bionics, Inc. (NASDAQ: BBNX) to determine whether certain Beta Bionics officers and directors violated securities laws and breached fiduciary duties to shareholders. Beta Bionics is a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes.

Jun 05, 2026 02:09 PM • globenewswire.com

Beta Bionics (BBNX) Securities Investigation: Johnson Fistel Reviews Investor Losses Following Slower New Patient Start Growth

SAN DIEGO, June 05, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential securities law violations on behalf of investors of Beta Bionics, Inc. (NASDAQ: BBNX). The investigation concerns whether Beta Bionics or certain of its executive officers made false or misleading statements, or failed to disclose material information, concerning the Company's growth trends, new patient starts, business outlook, and related operating metrics.

Jun 05, 2026 07:54 AM • globenewswire.com (Hide legal announcements)

Beta Bionics, Inc. (BBNX) Investigation: Johnson Fistel Investigates Investor Losses Following Slower New Patient Start Growth

SAN DIEGO, June 04, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating whether Beta Bionics, Inc. (NASDAQ: BBNX) or certain of its executive officers violated federal securities laws.

Jun 04, 2026 06:18 AM • globenewswire.com (Hide legal announcements)

Beta Bionics, Inc. Securities Fraud Investigation – Robbins LLP is Investigating Investor Losses in BBNX Due to Possible Violations of Securities Laws

Beta Bionics, Inc. Securities Fraud Investigation – Robbins LLP is Investigating Investor Losses in BBNX Due to Possible Violations of Securities Laws

Jun 03, 2026 12:09 PM • globenewswire.com

Beta Bionics Investors Suffer Significant Losses After Company Reports Slower New Patient Start Growth; Contact Johnson Fistel

SAN DIEGO--(BUSINESS WIRE)---- $bbnx #BBNX--Johnson Fistel, PLLP is investigating whether Beta Bionics, Inc. (NASDAQ: BBNX) or certain of its executive officers violated federal securities laws. The investigation focuses on investors' losses and whether they may be recovered under federal securities laws.What if I purchased Beta Bionics securities?If you purchased Beta Bionics securities and suffered losses on your investment, join our investigation now: Click Here to Join the Investigation.Or for more informat.

Jun 03, 2026 05:47 AM • businesswire.com (Hide legal announcements)

BBNX Shareholder Alert: Robbins LLP Reminds Beta Bionics, Inc. Stockholders that it is Investigating the Company's Officers and Directors to Determine if They Violated Securities Laws and Breached Fiduciary Duties to Shareholders

SAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) -- Shareholder rights law firm Robbins LLP is investigating Beta Bionics, Inc. (NASDAQ: BBNX) to determine whether certain Beta Bionics officers and directors violated securities laws and breached fiduciary duties to shareholders. Beta Bionics is a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes.

Jun 02, 2026 03:24 PM • globenewswire.com (Hide legal announcements)

Beta Bionics price target lowered to $17 from $19 at Goldman Sachs

$17.00 (was $11.72)

Goldman Sachs

May 27, 2026 06:17 AM • TheFly

Beta Bionics price target lowered to $20 from $40 at Lake Street

$20.00 (was $12.45)

Lake Street

Feb 18, 2026 08:42 AM • TheFly

Beta Bionics price target lowered to $14 from $28 at Baird

$14.00 (was $13.97)

Robert W. Baird

Feb 18, 2026 07:47 AM • TheFly

Beta Bionics price target lowered to $22 from $25 at Stifel

$22.00 (was $13.97)

Jonathan Block · Stifel Nicolaus

Feb 18, 2026 06:47 AM • TheFly

Beta Bionics initiated with a Buy at UBS

$24.00 (was $13.08)

UBS

Feb 08, 2026 04:13 PM • TheFly

Beta Bionics price target lowered to $25 from $31 at Stifel

$25.00 (was $14.06)

Stifel Nicolaus

Feb 04, 2026 08:09 AM • TheFly

Beta Bionics price target lowered to $25 from $37 at Truist

$25.00 (was $13.89)

Truist Financial

Feb 02, 2026 09:54 AM • TheFly

Beta Bionics initiated with a Hold at TD Cowen

$17.00 (was $15.46)

Cowen & Co.

Jan 26, 2026 04:41 PM • TheFly

Beta Bionics price target lowered to $25 from $33 at Goldman Sachs

$25.00 (was $16.99)

David Roman · Goldman Sachs

Jan 15, 2026 06:33 AM • TheFly

Beta Bionics price target raised to $40 from $35 at Lake Street

$40.00 (was $21.26)

Lake Street

Jan 09, 2026 08:46 AM • TheFly

Beta Bionics price target raised to $37 from $32 at Truist

$37.00 (was $30.45)

Richard Newitter · Truist Financial

Dec 18, 2025 09:09 AM • TheFly

Beta Bionics price target raised to $28 from $23 at Baird

$28.00 (was $29.73)

Robert W. Baird

Dec 16, 2025 05:37 AM • TheFly

Beta Bionics price target raised to $35 from $30 at Lake Street

$35.00 (was $24.28)

Frank Takkinen · Lake Street

Oct 29, 2025 08:44 AM • TheFly

Beta Bionics price target raised to $31 from $26 at Stifel

$31.00 (was $24.28)

Jonathan Block · Stifel Nicolaus

Oct 29, 2025 08:18 AM • TheFly

Beta Bionics price target raised to $33 from $26 at Goldman Sachs

$33.00 (was $24.28)

David Roman · Goldman Sachs

Oct 29, 2025 07:23 AM • TheFly

Beta Bionics price target raised to $23 from $17 at Baird

$23.00 (was $24.28)

Robert W. Baird

Oct 29, 2025 07:10 AM • TheFly

Beta Bionics price target raised to $32 from $26 at Piper Sandler

$32.00 (was $28.32)

Matt O'Brien · Piper Sandler

Oct 29, 2025 07:03 AM • TheFly

Beta Bionics, Inc. (BBNX) PT Raised to $32 at Truist Securities

$32.00 (was $24.28)

Richard Newitter · Truist Financial

Oct 29, 2025 07:01 AM • StreetInsider

Beta Bionics upgraded to Buy from Neutral at Goldman Sachs

$26.00 (was $19.87)

Goldman Sachs

Oct 01, 2025 05:11 AM • TheFly

Beta Bionics price target raised to $17 from $15 at Baird

$17.00 (was $16.76)

Robert W. Baird

Jul 30, 2025 08:48 AM • TheFly